ArticleThe World Allergy Organization journal2025
Predictive value of tissue eosinophilia for dupilumab response in chronic rhinosinusitis with nasal polyps: A retrospective monocentric study.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive value of baseline tissue eosinophilic infiltration (cells/high-power field [HPF]) in determining clinical response to dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: This retrospective, single-center observational study included patients with severe, refractory CRSwNP treated with dupilumab between December 2020 and December 2024. Based on histopathological analysis of nasal polyp biopsies, patients were stratified into 2 groups according to tissue eosinophil density: <50 cells/HPF and ≥50 cells/HPF. Clinical response was assessed through patient-reported outcomes (SNOT-22) and objective measures including Nasal Polyp Score (NPS), Lund-Kennedy Score (LKS), and Lund-Mackay Score (LMS), evaluated at baseline and after 1, 3, and 12 months of treatment. Repeated-measures ANOVA was used to evaluate within-group and between-group differences over time. Results: Eighty-six patients were included in the analysis: 57 with low eosinophilic infiltration (<50 cells/HPF) and 29 with high infiltration (≥50 cells/HPF). Patients with high tissue eosinophilia showed significantly greater improvement in SNOT-22 scores across all time points (p = 0.045). No significant between-group differences were found in endoscopic (NPS, LKS) or radiologic (LMS) outcomes throughout the follow-up period. Conclusions: Dupilumab confirmed high clinical efficacy, rapid symptom improvement, and good tolerability in patients with CRSwNP. Higher tissue eosinophil counts were associated with greater symptom improvement, as measured by SNOT-22. These findings suggest a potential role for tissue eosinophilia as a predictive marker of clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.